Document is current
Any future updates will be listed below
-
Authors
Johnson, Jeffrey A. http://orcid.org/0000-0001-8290-2857
Al Sayah, Fatima
Buzinski, Robert
Corradetti, Bonnie
Davison, Sara N.
Elliott, Meghan J.
Klarenbach, Scott
Manns, Braden
Schick-Makaroff, Kara
Short, Hilary
Thomas, Chandra
Walsh, Michael
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research (SCA-145103)
- License Information
-
More Information
Article History
Received: 24 June 2020
Accepted: 19 July 2020
First Online: 10 August 2020
Ethics approval and consent to participate
: Ethics approvals for the study were granted from all required institutions, including the University of Alberta (Health Research Ethics Board Pro00077850) and the University of Calgary (Conjoint Health Research Ethics Board REB18–0672). The ORN received ethics approvals from various regional authorities including Timmins and District Hospital Ethics and Research Committee, Bluewater Health Research Ethics Committee (2019-RES-01), Halton Healthcare Research Ethics Board, Joint Group Health Centre/Sault Area Hospital Research Ethics Board (2019-12-02), and Hamilton Integrated Research Ethics Board (1717). All ethics review boards approved the study to be conducted under a waiver of consent. This was considered appropriate because PROM collection was occurring already, or was planned to be implemented, as determined by the renal programs; the intervention (linking the PROM to patient/provider discussion) is of minimal risk to patients, and all treatments are ascribed based on the provider judgment, not by study protocol; seeking informed consent would not be feasible in the framework of making this part of routine clinical care; seeking informed consent would likely bias participation resulting in inaccurate estimations of effect which would render the results of the trial uninformative for the use of these measures as part of routine care. The University of Alberta’s Health Research Ethics Board and the University of Calgary’s Conjoint Health Research Ethics Board separately approved the qualitative sub-studies (HREB #Pro00085021, CHREB #REB18–1786, respectively).
: Not required.
: Fatima Al Sayah and Jeffrey Johnson are members of the EuroQol Group. J Johnson is a member of the Board of Directors for the EuroQol Research Foundation. Braden Manns is co-Principal Investigator of the Can-SOLVE CKD Network. All authors have no other conflicts of interest to declare.
